A pragmatic, open-label trial of osteoarthritis (OA) patients demonstrated that adding duloxetine treatment seems to be beneficial for end-stage knee OA patients with neuropathic-like symptoms (at risk of central sensitization).
Drs. Jack Cush and Artie Kavanaugh review the highlights of the RWCS (Rheumatology Winter Clinical Symposium) from Maui.
Why did I end up a rheumatologist? Circumstance, personality types, horoscopes or what? A current study in BMJ sheds light on why.
A physician cohort questionnaire-based study was distributed online survey tool, asking questions about zodiac sign, specialty preferences and personality features of physicians.
Rheumatologists looking for clues to whether their patients with certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study appearing in Arthritis Care & Research.
Using a large cohort of rheumatoid arthritis (RA) patients, Tumor-Necrosis Factor inhibitors (TNFi) were compared to non-TNFi biologic therapies and showed that poorer responses were seen in obese and underweight patients, with no clear superiority of non-TNFi therapy over TNFi therapy in any BMI category.
Patients enrolled in one of the pivotal trials of guselkumab (Tremfya) as therapy for psoriatic arthritis (PsA) and followed for 100 weeks continued to show significantly reduced symptoms relative to pretreatment baseline, researchers said.
The European League against Rheumatism (EULAR) has developed recommendations for cardiovascular risk (CVR) management in rheumatic disease patients based on literature review and expert consensus.
The consequences of medication non-adherence (NA) in rheumatoid arthritis (RA) care are numerous and damaging. A 6-month prospective cohort study of RA patients shows NA to vary according to drug type and be related to psychological, communicational, logistic, sociodemographic or clinical factors.
My uncle is going through medical hell. As a committed iatrophobic (fear of doctors), any mention of phlebotomy, tests, needles or a clinic visit evokes flop-sweat. Since being slapped with a cancer diagnosis, he has overcome a lot, and much to my surprise has bravely done so.
When I asked how he has adapted so well to the medical onslaught he now leans into, his answer was quick and poignant.
Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.
The integration of Telemedicine in to rheumatologic care was ignited by pandemic restrictions in early 2020 and since the advantages and disadvantages have been debated.
Arthritis & Rheumatology has published the results of the Nor-Hand study, showing that pain hand osteoarthritis (OA) was related to a higher body mass index (BMI) and also to inflammatory adipokines, such as leptin.
The Nor-Hand study enrolled 281 hand OA patients, assessed their pain in multiple joints, overall pain with several indices, including the WOMAC, NRS and AUSCAN and measured inflammatory biomarkers.
A Task Force from the ACR has provided an updated (version 3) guidance for the diagnosis and management of Multisystem Inflammatory Syndrome in Children (MIS-C), a COVID related condition characterized by fever, inflammation, and multiorgan dysfunction. The current guidance also applies to children with hyperinflammation during COVID-19, the acute, infectious phase of SARS–CoV-2 infection.
Osteoarthritis (OA) of the hand was less severe according to objective and pain-related markers in Black patients versus those of other racial/ethnic groups after adjustment for known risk factors, researchers found.
The results of the VITAL study (presented at ACR 2021) are now published by BMJ, showing that vitamin D and omega 3 fatty acids reduce the overall risk of autoimmune disease (AID) in a population based intervention trial.
